Recombinant Human SPARC-like 1/SPARCL1 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human SPARC-like 1/SPARCL1 Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit the cell growth of Mv1Lu mink lung epithelial cells. Schiemann, B.J. et al. (2003) Mol. Biol. Cell. 14:3977. The ED₅₀ for this effect is 0.5-2.0 µg/mL.
• Source: Mouse myeloma cell line, NS0-derived human SPARC-like 1/SPARCL1 protein
  Ile17-Phe664, with a C-terminal 10-His tag
• Accession #: Q8N4S1
• N-terminal Sequence: Ile17
• Protein/Peptide Type: Recombinant Proteins
• Gene: SPARCL1
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 74.9 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 118-144 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human SPARC-like 1/SPARCL1 Protein, CF

• Hevin
• High endothelial venule protein
• MAST 9
• MAST9
• PIG33
• proliferation-inducing protein 33
• SC1
• SPARC like 1
• SPARCL1
• SPARC-like 1 (hevin)
• SPARC-like 1 (mast9, hevin)
• SPARC-like 1
• SPARC-like protein 1

Background

SPARCL1 (Secreted Protein, Acidic and Rich in Cysteines-like 1), also known as hevin, SC1 or MAST9, is a member of the SPARC family of extracellular glycoproteins (1, 2). SPARCL1 is an anti-adhesive protein that is widely expressed in tissues such as brain, heart, lung, muscle and kidney, but not liver (3, 4). Human SPARCL1 contains a 16 amino acid (aa) signal sequence and a 648 aa mature region with four domains: a 416 aa N-terminal acidic region, a 23 aa
follistatin-like domain, a 55 aa kazal-like segment and a 48 aa EF-hand/calcium-binding domain (3, 4). SPARCL1 is predicted at 75 kDa, but migrates at ~130 kDa, which has been explained either by disulfide-linked homodimerization or by glycosylation and high acidity (3-5). Some truncated forms have been reported. In mouse, a 55 kDa C-terminal fragment is the only form in kidney and represents a portion of SPARCL1 in other tissues (6). In humans, a 25 kDa form is increased in liver tumors that are encapsulated, while the full-length form is down-regulated in many epithelial cell-derived tumors (7, 8). SPARCL1 inhibits adhesion and spreading on a variety of substrates (5, 9). It is thought to cause antiadhesive signaling that terminates neuronal migration, consistent with production by glial and neuronal cells during development or in response to trauma (10). In tonsillar high endothelial venules (HEV), SPARCL1 may induce endothelial cell dissociation, promoting extravasation (3). SPARCL1 binds collagen; in mice, deletion causes dermal collagen fibrils that are smaller in diameter and deficient in decorin (6, 11). Human mature SPARCL1 shares 67%, 69%, 78%, 76%, 72% and 72% aa identity with mouse, rat, equine, canine, porcine and bovine SPARCL1, respectively. The follistatin-like, kazal-like and calcium-binding domains of SPARCL1 show 61% aa identity with corresponding regions of SPARC.

1. Framson, P. E. and E. H. Sage (2004) J. Cell. Biochem. 92:679.
2. Sullivan, M. M. and E. H. Sage (2004) Int. J. Biochem. Cell Biol. 36:991.
3. Girard, J. P. and T. A. Springer (1995) Immunity 2:113.
4. Bendik, I. et al. (1998) Cancer Res. 58:626.
5. Brekken, R. A. et al. (2004) J. Histochem. Cytochem. 52:735.
6. Hambrock, H. O. et al. (2003) J. Biol. Chem. 278:11351.
7. Lau, C. P. et al. (2006) J. Pathol. 210:469.
8. Isler, S. G. et al. (2001) Int. J. Oncol. 18:521.
9. Girard, J. P. and T. A. Springer (1996) J. Biol. Chem. 271:4511.
10. Gongidi, V. et al. (2004) Neuron 41:57.
11. Sullivan, M. M. et al. (2006) J. Biol. Chem. 281:27621.

Publications for SPARC-like 1/SPARCL1 (2728-SL)(4)

Publications using 2728-SL

• SJ Zhao, YQ Jiang, NW Xu, Q Li, Q Zhang, SY Wang, J Li, YH Wang, YL Zhang, SH Jiang, YJ Wang, YJ Huang, XX Zhang, GA Tian, CC Zhang, YY Lv, M Dai, F Liu, R Zhang, D Zhou, ZG Zhang SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/?-catenin signaling through stabilization of the WNT-receptor complex Oncogene, 2017-10-30;0(0):. 2017-10-30 [PMID: 29084211] (Bioassay, Human)
• Elisabeth Naschberger, Andrea Liebl, Vera S. Schellerer, Manuela Schütz, Nathalie Britzen-Laurent, Patrick Kölbel et al. Matricellular protein SPARCL1 regulates tumor microenvironment–dependent endothelial cell heterogeneity in colorectal carcinoma Journal of Clinical Investigation 2016-10-10 [PMID: 27721236] (Bioassay, Human)
• Joanna L. Richens, Hannah L. Spencer, Molly Butler, Fiona Cantlay, Kelly-Ann Vere, Nin Bajaj et al. Rationalising the role of Keratin 9 as a biomarker for Alzheimer’s disease Scientific Reports 2016-03-14 [PMID: 26973255] (ELISA Standard, Human)
• Chaurasia S, Perera P, Poh R, Lim R, Wong T, Mehta J Hevin plays a pivotal role in corneal wound healing. PLoS ONE, 2013-11-26;8(11):e81544. 2013-11-26 [PMID: 24303054] (In Vivo, Mouse)

Bioinformatics

• Gene Symbol: SPARCL1
• Uniprot:
  • Q8N4S1()